Chiasma Reports Fourth Quarter and Year End 2018 Results
08. März 2019 16:05 ET
|
Chiasma, Inc.
On track for top-line data from Phase 3 CHIASMA OPTIMAL trial of octreotide capsules, conditionally trade-named MYCAPSSA®, expected in Q3 2019 Assuming positive OPTIMAL data, NDA submission expected...
Chiasma to Participate in Three Investor Conferences in March
04. März 2019 16:05 ET
|
Chiasma, Inc.
WALTHAM, Mass., March 04, 2019 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic...
Chiasma Announces Support for Rare Disease Day 2019
28. Februar 2019 08:00 ET
|
Chiasma, Inc.
WALTHAM, Mass., Feb. 28, 2019 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic...
Chiasma Previews Important Upcoming Milestones
03. Januar 2019 16:05 ET
|
Chiasma, Inc.
CHIASMA OPTIMAL Phase 3 topline data expected in Q3 2019 Company anticipates submitting U.S. NDA by year-end 2019, assuming positive CHIASMA OPTIMAL data, and if accepted for filing, further...
Chiasma Reports Third Quarter 2018 Results
08. November 2018 16:05 ET
|
Chiasma, Inc.
Topline Data from Phase 3 CHIASMA OPTIMAL Trial of Octreotide Capsules, Conditionally Trade-Named MYCAPSSA®, Anticipated by September 2019 Company randomizes 80th patient in Phase 3 MPOWERED™...
Chiasma Supports Acromegaly Awareness Day
01. November 2018 08:00 ET
|
Chiasma, Inc.
Company continues to advance its novel octreotide capsules candidate through Phase 3 clinical trials in the U.S. and E.U. WALTHAM, Mass., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ:...
Chiasma Announces Oral Presentation at the 18th Congress of the European Neuroendocrine Association
17. Oktober 2018 16:05 ET
|
Chiasma, Inc.
Presentation by Dr. Maria Fleseriu, a widely-published endocrinologist and recognized thought leader in the field of acromegaly WALTHAM, Mass., Oct. 17, 2018 (GLOBE NEWSWIRE) -- Chiasma, Inc....
Chiasma Completes Enrollment of CHIASMA OPTIMAL Phase 3 Clinical Trial of Octreotide Capsules in Patients with Acromegaly
01. Oktober 2018 16:01 ET
|
Chiasma, Inc.
Topline data now expected in September 2019, versus prior guidance of 4Q 2019 WALTHAM, Mass., Oct. 01, 2018 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a clinical-stage biopharmaceutical...
Chiasma Announces Poster Presentation at the 9th International Congress of the Growth Hormone Research and IGF Societies
13. September 2018 16:01 ET
|
Chiasma, Inc.
Among the initial findings, some acromegaly patients managed by injectable somatostatin receptor ligands (SRLs) report symptoms that may interfere with daily life Treatment burden associated with...
Chiasma to Present at the H.C. Wainwright 20th Annual Global Investment Conference
29. August 2018 16:05 ET
|
Chiasma, Inc.
NEW YORK, Aug. 29, 2018 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic...